2003
Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression
Mulherin S, O'Brien T, Ioannidis J, Goedert J, Buchbinder S, Coutinho R, Jamieson B, Meyer L, Michael N, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Theodorou I, Vlahov D, Rosenberg P. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression. AIDS 2003, 17: 377-387. PMID: 12556692, DOI: 10.1097/00002030-200302140-00012.Peer-Reviewed Original ResearchConceptsHIV-1 disease progressionHIV-1 seroconvertersCCR5-Delta32CCR2-64ICourse of infectionDisease progressionLower riskChemokine receptor gene polymorphismsCox proportional hazards modelHIV-1 infectionIndividual patient dataCCR2-64I alleleProportional hazards modelReceptor gene polymorphismsCCR2-64I.Disease courseSurvival benefitHazards modelGene polymorphismsCCR5-Δ32Significant protectionAIDSPatient dataInfectionSeroconverters
1996
An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users
Hershow R, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, Klein R, Jarlais D, Vitek C, Khabbaz R, Freels S, Zuckerman R, Pezzotti P, Kaplan J. An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users. The Journal Of Infectious Diseases 1996, 174: 309-317. PMID: 8699060, DOI: 10.1093/infdis/174.2.309.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell percentCell percentHuman immunodeficiency virus type 1 (HIV-1) disease progressionHuman immunodeficiency virus type 1 (HIV-1) infectionDrug usersInfected injection drug usersVirus type 1 infectionHuman T-lymphotropic virus type IIHIV seroconversion datesHTLV-II infectionType 1 infectionProportional hazards modelEffect of coinfectionSeroconversion datesCohort studyHIV infectionHTLV infectionDisease progressionAIDS mortalityHTLV-IIHazards modelRate of declineInternational collaborative studyWestern blot
1994
Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users
Aylward R, Vlahov D, Muñoz A, Rapiti E. Validation of the proposed World Health Organization staging system for HIV disease and infection in a cohort of intravenous drug users. AIDS 1994, 8: 1129-1134. PMID: 7986411, DOI: 10.1097/00002030-199408000-00015.Peer-Reviewed Original ResearchConceptsIntravenous drug usersClinical stage 1Proportional hazards modelStaging systemProduct limit estimatesWorld Health OrganizationALIVE studyHIV diseaseHazards modelPopulation of IVDUWorld Health Organization (WHO) staging systemDrug usersCox proportional hazards modelStage 1WHO staging systemTime of progressionStage 2Index visitHIV seropositivityHIV-seropositivePrognostic utilityClinical stageClinical criteriaOriginal cohortClinical signs